VECT News and Press, VectivBio Holding AG From 11/03/22

-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes -First Phase 3 study to prospectively evaluate safety and efficacy of a GLP-2 agonist in SBS-IF according to patient’s remnant...

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced ...

VectivBio ( NASDAQ: VECT ) reported interim data from an ongoing phase 2 trial of apraglutide to treat adult patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC). The study is evaluating the effects of once-weekly aprag...

VectivBio Holding ( NASDAQ: VECT ) prices an underwritten offering of 16.7M ordinary shares at an offering price of $7.50/share for gross proceeds of ~$125M. The offering is expected to close on or about October 17, 2022. The company intends to use the net proceeds fro...

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering ...

•  Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months •  80% of patients were clinical responders (defined as a reduction in volume of PS of at least 20%) and achieved at least one day ...

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Me...

Piper Sandler started off coverage on clinical stage biopharma company VectivBio Holding ( NASDAQ: VECT ) with the Overweight rating. The investment bank has set a price target of $23 on VectivBio, which implies a potential upside of 325% from stock's last close to land near t...

Gainers: Accolade ( ACCD ) +18% . Clovis Oncology ( CLVS ) +18% . Larimar Therapeutics ( LRMR ) +14% . Tyra Biosciences ( TYRA ) +13% . VectivBio Holding ( VECT ) +13% . Losers: Talaris Therapeutics ( TALS ) -48% . Agile Therapeu...

BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced...